Fig. 4From: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trialStatistical design. CT Computed tomography, MRD Minimal residual disease, WHO World Health OrganisationBack to article page